Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 447-920-2
CAS number: 897393-42-9
The acute oral toxicity test with the test substance showed
the LD50 being between 200 and 2000 mg/kg body weight. The
subacute toxicity test for 28-days revealed a NOAEL of 50
mg/kg/day. Therefore, an extensive toxicokinetic assessment
is considered of limited value. Below, a summary of the
anticipated toxicokinetic behaviour of the test substance is given.
The water solubility of the test substance is high. Since in
general a compound needs to be dissolved before it can be
taken up from the gastro-intestinal tract, it is likely that
the test substance will show a high systemic exposure after
oral administration. It is to be expected that the oral
bioavailability of the test substance will be relatively
high. The highest absorption is expected to be from the duodenum.
In the gastro-intestinal tract, hardly any degradation of
the substance is to be expected. In the case absorption of the
test substance occurs, the aliphatic carbons as well as the
primary nitrogens will undergo extensive hydroxylation,
followed by rapid sulfation or glucuronidation. Direct
conjugation at the nitrogens in the parent compound is
expected. Also extensive cleavage of the ether bonds is
anticipated. The resulting metabolites will be extensively
excreted via bile and/or urine.
The submission substance will show a low volume of distribution,
because of the relatively low lipophilicity of the compound.
The volume of distribution is expected to equal total body
water (about 700 ml/kg). Accumulation in fatty tissues is
therefore not anticipated. The plasma protein binding is
expected to be low.
Uptake via inhalation may take place based on the vapour pressure.
Since it is generally accepted that substances with log Po/w
ranging from 0.1 to 6 penetrate the skin easily, it is
to be expected that the test substance may penetrate the
skin rapidly. The fact that the test substance is corrosive
to the skin may even increase the dermal absorption.
Based on the expected kinetic behaviour in the body, as
described above, the test substance will show a relatively
high absorption after oral administration, mainly because of
its high water solubility. If absorption occurs, the test
substance will be extensively metabolised in the liver and
rapidly excreted via bile and/or urine. Therefore,
accumulation in the body during prolonged exposure will be very low.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
På den här webbplatsen används kakor. Syftet är att optimera din upplevelse av den.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again